Estimated read time: 4-5 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
[STK]
[IN] HEA
[SU] NPT
TO BUSINESS, AND HEALTH EDITORS:
Uniting Against Lung Cancer Reaches New Funding Heights, Awarding Over
$1.5 Million in Lung Cancer Research Grants
NEW YORK, April 25, 2014 /PRNewswire/ -- Uniting Against Lung Cancer
(UALC), a nonprofit dedicated to funding innovative research and
raising awareness for lung cancer, announces that it has achieved a
new level of funding this year, committing more than $1.5 million in
lung cancer research grants to premier medical and research
institutions across the country. This contribution brings UALC's total
funding for lung cancer research grants to a total of $11.5 million.
Lung cancer is the nation's deadliest cancer, responsible for over
220,000 new diagnoses and nearly 160,000 cancer deaths each year. With
the support of its partners across the country, UALC funds the
critical research that will improve treatment options, extend
survival, and find a cure for lung cancer patients. These efforts have
led to more than $55 million in continued support from federal and
public sources, new therapies in clinical trials, and major advances
improving treatment for thousands of lung cancer patients.
Recipients of funding are selected by the UALC Medical Committee,
comprised of the top physicians and scientists in the field. This
year's grantees are developing new methods for early detection of lung
cancer; investigating new targets and novel therapies for both small
cell and non small cell lung cancer; and gaining a greater
understanding of the origins of lung cancer to find a cure for the
nation's leading cancer killer.
New funding opportunities will be open to applicants in May 2014.
Visit http://www.unitingagainstlungcancer.org/research for more
details.
Recipients of UALC funding are:
Collin Blakely, MD, PhD University of California, San Francisco
Evolution and impact of tumor molecular heterogeneity on response to
EGFR-targeted lung cancer therapy Sponsored by Uniting Against Lung
Cancer and Free to Breathe
Emily Cheng, MD, PhD Memorial Sloan-Kettering Cancer Center Targeting
the BCL-2 Family in Small Cell Lung Cancer Sponsored by The Judy &
Fred Wilpon Foundation and Tishman Speyer
William Cheung, PhD Yale University Treating metastasis by
differentiation therapy: Identifying druggable pathways Sponsored by
The Tom Zangas Lung Cancer Foundation and the Mike Pascucci Lung
Cancer Association
Curtis Chong, MD, PhD Dana-Farber Cancer Institute Combination
screening of targeted therapies as a strategy to understand and
overcome resistance to EGFR inhibitors in lung cancer patients
Sponsored by the Marjorie M. Fisher Fund, the Tighe-Hidalgo
Foundation, and the Office of Dr. David Hidalgo
Subhajyoti De, PhD University of Colorado, Denver Identifying
potential driver mutations in gene promoters in a cohort of completely
sequenced NSCLC genomes Sponsored by Elliot's Legacy and Joan's Legacy
Anna Farago, MD, PhD Massachusetts General Hospital Cancer Center
Leveraging genetically engineered preclinical models of small cell
lung cancer for advanced therapeutic studies Sponsored by Elliot's
Legacy and Joan's Legacy
Christine Fillmore, PhD Children's Hospital Boston Epigenetic
inhibitors in personalized therapy for Brg1 and EGFR mutant lung
tumors Sponsored by Joan's Legacy in honor of Meryl Bralower
Zeynep Gumus, PhD Weill Cornell Medical College Identification of
Constitutional Risk Genes for Non-Small Cell Lung Cancer
Adenocarcinoma Sponsored by The Ira Waldbaum Family Foundation and The
Malinsky Family Charitable Trust
Sandra Hofmann, PhD University of Texas Southwestern Medical Center
DHHC Protein Palmitoyltransferases in Small Cell Lung Cancer Sponsored
by Elliot's Legacy and Joan's Legacy
Matthew Niederst, PhD Massachusetts General Hospital Cancer Center
Determining the mechanisms of intrinsic and acquired resistance to the
3rd generation EGFR inhibitor CO-1686 Sponsored by Pershing Square
Capital Management and Joan's Legacy
Ann Marie Pendergast, PhD Duke University Medical Center Novel
druggable pathway required for lung cancer progression and metastasis
Sponsored by The Hank Thompson Fund, Lily's Light, and the Caine
Halter Fund for Lung Cancer Research
David Shackelford, MD, PhD University of California, Los Angeles
Targeting LKB1-deficient non-small cell lung cancer through the NRF2
pathway Sponsored by Greenlight Capital and The Durst Organization
Takeshi Shimamura, PhD Loyola University Chicago BET bromodomain
inhibitor resistance in LKB1 deficient mutant KRAS NSCLC Sponsored by
Chicago Lung Run
Ferdinandos Skoulidis, MD, PhD MD Anderson Cancer Center Impact of NF1
inactivation on the pathogenesis, signaling circuitry and therapeutic
responsiveness of NSCLC in a novel co-clinical trial of targeted
therapy Sponsored by Elliot's Legacy and Joan's Legacy
Alison Taylor, PhD Dana-Farber Cancer Institute Chromosomal Gains in
Lung Squamous Carcinoma Sponsored by the Nancy Raisman Memorial Fund
To see a complete description of the funded projects and to learn more
about supporting UALC Scientific Programs, visit
http://www.unitingagainstlungcancer.org/research
About Uniting Against Lung Cancer Uniting Against Lung Cancer is
dedicated to funding innovative research that enables patients,
smokers and non-smokers alike, to win their battles with lung cancer
and live healthy, cancer-free lives years after diagnosis. UALC and
its Partners across the country raise awareness and critical funds for
lung cancer research. For more information, please visit
www.UnitingAgainstLungCancer.org.
Contact: Uniting Against Lung Cancer
Holli Kawadler - 212-627-5500
Great Ink Communications
Roxanne Donovan- 212-741-2977
Read more news from Uniting Against Lung Cancer.
SOURCE Uniting Against Lung Cancer
-0- 04/25/2014
/Web Site: http://www.unitingagainstlungcancer.org
CO: Uniting Against Lung Cancer
ST: New York
IN: HEA
SU: NPT
PRN
-- PH12668 --
0000 04/25/2014 12:35:00 EDT http://www.prnewswire.com
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
